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Introduction
Atypical hemolytic uremic syndrome 
(aHUS) is an immune disorder 
stemming from dysregulation of the 
alternative complement pathway, leading 
to complement overactivation. The 
disease presents as a combination of 
thrombotic microangiopathy (TMA), 
thrombocytopenia, and renal failure. 
Although rare with an estimated prevalence 
of approximately 0.11 new cases/million 
population/year,[1,2] it has a very high 
mortality and morbidity that extends far 
beyond the initial presentation period.[3] The 
approval of eculizumab (Soliris, Alexion 
Pharmaceuticals, Inc., Cheshire, CT, 
USA) on September 23, 2011, as an 
orphan drug marked a breakthrough for 
this  condition,  as  it was  the  first  Food  and 
Drug Administration‑approved treatment 
for aHUS; an untreatable disease suddenly 
became treatable. International guidelines 
place  eculizumab  as  a  first‑line  treatment 
in patients with a clinical diagnosis of 
aHUS  (confirmation  of  a  complement 
mutation is not required) that should 
be  initiated  within  24–48  h  of  onset  or 
admission.[4] This quick initiation is to 
achieve the best outcome with regard to 
ultimate renal recovery and to diminish 
the risk of early progression to end‑stage 
renal disease.[5‑7] However, its dosing 
presents a problem in pediatrics. The 
current dosing recommendations on the 
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Abstract
Eculizumab is the therapy of choice for patients with atypical hemolytic uremic syndrome (aHUS). 
Dosing recommendations stem from two trials: one retrospective trial (19 children and 5 infants) and 
one prospective trial (22 patients and 5 infants). This case report highlights the need for more precise 
dosing recommendations in children, particularly in infants, and for smaller vials of the medication 
to facilitate more precise dosing. Such changes would ensure that adverse events are minimized 
and that the children with aHUS who are treated with eculizumab experience an optimal clinical 
response.
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eculizumab product label[8,9] are weight 
based in increments of 5 kg and then 
10  kg:  5–9.9  kg,  10–19.9  kg,  20–29.9  kg, 
30–39.9  kg,  and  40  kg  and  over.  The 
approval for the aHUS indication in 
children was originally made based on one 
retrospective chart review study outside 
of a controlled clinical trial setting in 
19 children under the age of 18 years, with 
15 of those under the age of 12 years of 
age and 5 under 2 years of age.[10,11]
One prospective pediatric study has been 
published since eculizumab was approved 
by the major regulatory agencies to treat 
aHUS; the intent‑to‑treat population of this 
study was 22, while only 19 completed 
26 weeks of treatment. Of these children, 
only one was younger than 1 year of 
age  (personal  communication),  five  were 
below 2 years of age, and 18 were below 
12 years of age.[12] The composition of 
both of these study cohorts suggests that 
the dosing for children, particularly for 
newborns, infants, and toddlers, was 
extrapolated from a handful of patients. 
Since this period brings rapid changes in 
growth and ontogeny in drug disposition, 
pediatric dosing recommendations must 
be exact, and medications for children 
are typically dosed either per kilogram of 
body weight or per m2 of the child’s body 
surface area (BSA) rather than in vague 
weight increments. We detail the case of 
the youngest patient in Canada with aHUS 
to be treated with eculizumab and describe 
the associated dosing challenges.
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Case Report
An 8‑month‑old previously healthy, fully immunized, 
formula‑fed female presented to the emergency room 
with a short history of an upper respiratory tract 
infection  (confirmed  respiratory  syncytial  virus),  feeding 
intolerance, emesis (nonbilious and nonbloody), reduced 
urine output, no diarrhea, and no contact with farm animals 
or cow milk products. One day after her admission, 
while afebrile, she was somnolent, pale, had slight 
jaundice, and mild dehydration. Her urine output did not 
improve following rehydration. She was transferred to 
a tertiary care center, where testing revealed the blood 
parameter levels as shown in Table 1.
Based on these results, she was diagnosed with systemic 
TMA.
Her urinary sediment was very active. Her ADAMTS 13 
(a disintegrin and metalloproteinase with a thrombospondin 
Type 1 motif, member 13) activity was >69% (reference 
interval  41%–130%),  ruling  out  thrombocytopenic 
purpura, and her stool was negative for Escherichia 
coli O157: H7, ruling out Shiga toxin‑producing 
E. coli‑HUS. The differential diagnosis was therefore 
aHUS. Her complement C3 activity was normal, but 
her CH50 activity was undetectable. The genetic 
workup  confirmed  the  presence  of  a  pathogenic  variant 
(c.3546G>C [Arg1182Ser]) and of a variant of uncertain 
significance (C.3148A>T [Asn1050Tyr]) in the complement 
factor H (CFH) gene (laboratory of Dr. Christoph Licht, 
Hospital for Sick Children, Toronto, Canada), while there 
were no anti‑CFH antibodies. Treatment consisted of 
plasma infusion therapy (up to 55 ml/FFP/kg) and four 
treatments with plasma exchange with up to 1.5 times 
of the patient’s plasma volume. She also received two 
blood transfusions. Platelets, urine output, and creatinine 
normalized. No steroids or other agents were given. Three 
weeks later, she relapsed in association with an upper 
respiratory tract infection. As there was no antibody titer 
detectable at initial presentation, this was not reevaluated. 
At this time, her hemoglobin dropped to 67 g/L, her 
platelets dropped to 52 × 109/L, lactate dehydrogenase 
rose to 1266 U/L, haptoglobin was undetectable, and she 
required three transfusions. After receiving a meningococcal 
conjugate vaccine, she was started on eculizumab, in 
accordance with the consensus guidelines. With a weight 
of 9.17 kg, she was initially given one 300 mg dose for 
the 1st week of induction, then 300 mg 1 week later and 
300 mg every 3 weeks during the maintenance phase, 
as per the manufacturer’s instructions. Her platelet 
count  normalized  after  the  first  two  treatments  and  her 
haptoglobin normalized after 14 weeks. Interestingly, the 
patient would experience feeding intolerance and vomiting 
on day 16 following each treatment. Treatment was 
accelerated to 18‑day and then 17‑day intervals without any 
improvement in her day 16 symptoms; the dosing interval 
was therefore shortened to 14 days. Finally, the patient’s 
vomiting subsided with 14‑day treatment intervals, and for 
the first  time,  after not having gained any weight  from  the 
time of presentation, she gained some weight to 9.4 kg 
following  the  first  14‑day  treatment  interval.  Her  weight 
dropped from the 92nd to the 52nd percentile. Her CH50 
complement activity remained undetectable. The results 
of tests to measure eculizumab concentration are currently 
pending.  Her  cystatin  C  estimated  glomerular  filtration 
rate remains abnormal at 71 ml/min 1.73 m2 following 
8 months of therapy [Figure 1].
Discussion
Great strides have been made within the last 15 years in 
understanding the pathophysiology of aHUS, and scientists 
are still elucidating the genetic background of this disease 
by continuing to identify new genetic mutations associated 
with aHUS. The publication of comprehensive international 
guidelines for diagnosing and treating pediatric aHUS in 
January of 2016 in Pediatric Nephrology[4] also represents a 
significant  advancement  in  physicians’  abilities  to  properly 
diagnose aHUS in children. Since, until very recently, an 
aHUS diagnosis entailed a grim outlook and often death, 
new guidelines and a new treatment will most likely result 
in a greater number of diagnoses that will be made more 
quickly and will be more accurate. In the prospective 
pediatric eculizumab trial by Greenbaum et al.,[12] a post hoc 
Table 1: Blood parameter results at presentation
Blood parameters at presentation
Parameter Result Reference 
interval
Condition
Platelet count 48×109/L 150‑400×109/L Thrombocytopenia
Hemoglobin 60 (g/L) 100‑140 (g/L) Hemolytic anemia
Lactate 
dehydrogenase
4909 (U/L) <300 (U/L)
Haptoglobin Undetectable 0.26‑2.26 (g/L)
Serum creatinine 47 (µmol/L) <33 (µmol/L) Impaired renal 
function
Figure 1: Chronological cystatin C estimated glomerular filtration rate and 
haptoglobin measurements from the time of admission. Vomiting is marked 
according to its duration and eculizumab treatments are marked with arrows
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analysis examining the children who did and did not meet 
criteria for the primary endpoint at 26 weeks, which was 
defined  as  a  complete  TMA  response,  revealed  a  stark 
difference  in  the median  age  at  first  infusion.  The median 
age  at  first  infusion  of  children who  achieved  the  primary 
endpoint was 7.5 years, while the median age of those 
who did not was 2.0 years. This suggests that the younger 
children tended to be underdosed and that eculizumab has 
a shorter half‑life in children, so they were less likely to 
achieve the primary endpoint when dosed according to 
the current guidelines. This case study, where eculizumab 
dosing in the <10 kg weight category was empirically 
escalated, eventually resulting in a clinical remission, 
highlights the need for more infant data to refine the current 
pediatric eculizumab dosing guidelines. With the likelihood 
that  the  identified prevalence of  aHUS will  increase  in  the 
coming  years,  it  is  important  to  refine  eculizumab  dosing 
in children, particularly in younger children. In addition 
to recruiting more patients and collecting more data to 
establish more precise dosing per kilogram of body weight 
or per m2 of BSA, smaller vials should be produced to 
implement more accurate dosing. Vials of 50 mg, 100 mg, 
or  even  150  mg  would  be  highly  beneficial  to  clinicians. 
In the absence of additional pediatric pharmacokinetic 
studies and precise guidelines, physicians should observe 
the patient’s clinical response and adjust the patient’s dose 
to minimize any adverse effects. The clinician should also 
employ pharmacokinetic monitoring if the patient’s clinical 
response is insufficient and adjust the dose accordingly.
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